Search research articles
Contact Us
Filters
Showing results (431-440 of 453) with videos related to
Page
of 46
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 14, 2011
Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study
T Jouary, C Leyral, B Dreno, et al.
Schweizerische Medizinische Wochenschrift
|
August 25, 1973
[Clinical immunological tests]
S Barandun, R Bütler, H Carmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 28, 2015
A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma
E M Hersh, M Del Vecchio, M P Brown, et al.
Schweizerische Medizinische Wochenschrift
|
January 1, 1977
[Clinical-immunological tests; current state]
P J Grob, S Barandun, H Carmann, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 29, 2024
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients
C Robert, G V Long, J Larkin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 26, 2020
Response to: Comment on 'Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines'
Ketty Peris, Maria C Fargnoli, Claus Garbe, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 4, 2020
Comment on 'Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines'
Ketty Peris, Maria C Fargnoli, Claus Garbe, et al.
Molecular Cancer Therapeutics
|
November 5, 2016
HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib
Michael F Press, Catherine E Ellis, Robert C Gagnon, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 23, 2023
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial
E Livingstone, H Gogas, L Kandolf-Sekulovic, et al.
ESMO Open
|
November 16, 2016
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study
R Gutzmer, L Rivoltini, E Levchenko, et al.
Page
of 46
Search research articles
Search
Showing results (431-440 of 453) with videos related to
Sort By:
Page
of 46
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 14, 2011
Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study
T Jouary, C Leyral, B Dreno, et al.
Schweizerische Medizinische Wochenschrift
|
August 25, 1973
[Clinical immunological tests]
S Barandun, R Bütler, H Carmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 28, 2015
A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma
E M Hersh, M Del Vecchio, M P Brown, et al.
Schweizerische Medizinische Wochenschrift
|
January 1, 1977
[Clinical-immunological tests; current state]
P J Grob, S Barandun, H Carmann, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 29, 2024
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients
C Robert, G V Long, J Larkin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 26, 2020
Response to: Comment on 'Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines'
Ketty Peris, Maria C Fargnoli, Claus Garbe, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 4, 2020
Comment on 'Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines'
Ketty Peris, Maria C Fargnoli, Claus Garbe, et al.
Molecular Cancer Therapeutics
|
November 5, 2016
HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib
Michael F Press, Catherine E Ellis, Robert C Gagnon, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 23, 2023
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial
E Livingstone, H Gogas, L Kandolf-Sekulovic, et al.
ESMO Open
|
November 16, 2016
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study
R Gutzmer, L Rivoltini, E Levchenko, et al.
Page
of 46